Monoclonal antibody mechanisms of action in cancer

ISSN： 0257-277X

Source： Immunologic Research, Vol.39, Iss.1-3, 2007-11, pp. : 271-278

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Monoclonal Antibody First Dose Cytokine Release Syndromes–Mechanisms and Prediction

By Wing Mark

Journal of Immunotoxicology, Vol. 5, Iss. 1, 2008-06 ,pp. : 11-15

Informa Healthcare

Access to resources Recommend Favorite

Duration of action of a chimeric interleukin-2 receptor monoclonal antibody, basiliximab, in pediatric kidney transplant recipients

By Sterkers G. Baudouin V. Ansart-Pirenne H. Maisin A. Niaudet P. Cochat P. Loirat C.

Transplantation Proceedings, Vol. 32, Iss. 8, 2000-12 ,pp. : 2757-2759

Elsevier

Access to resources Recommend Favorite

Recombinant monoclonal antibody technology

By Siegel D.L.

Transfusion Clinique et Biologique, Vol. 9, Iss. 1, 2002-01 ,pp. : 15-22

Elsevier

Access to resources Recommend Favorite

Considerations for in vitro monoclonal antibody production

By Peterson N.C.

Research in Immunology, Vol. 149, Iss. 6, 1998-07 ,pp. : 553-557

Elsevier

Access to resources Recommend Favorite

Monoclonal antibody production: problems and solutions

By Falkenberg F.W.

Research in Immunology, Vol. 149, Iss. 6, 1998-07 ,pp. : 542-547

Elsevier

Access to resources Recommend Favorite